It appears that although temsirolimus demonstrated significant anti-tumour activity across all histological subtypes, the differential gain in efficacy of temsirolimus versus IFN seemed to be greatest in non-clear cell RCC. The gene discussed is IFNA1; the disease is neoplasm.